Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 682

1.

Creation and Initial Characterization of Isogenic Helicobacter pylori CagA EPIYA Variants Reveals Differential Activation of Host Cell Signaling Pathways.

Bridge DR, Blum FC, Jang S, Kim J, Cha JH, Merrell DS.

Sci Rep. 2017 Sep 8;7(1):11057. doi: 10.1038/s41598-017-11382-y.

2.

The role of Notch signaling in gastric carcinoma: molecular pathogenesis and novel therapeutic targets.

Yao Y, Ni Y, Zhang J, Wang H, Shao S.

Oncotarget. 2017 May 11;8(32):53839-53853. doi: 10.18632/oncotarget.17809. eCollection 2017 Aug 8. Review.

3.

Gastric xanthoma is a predictive marker for metachronous and synchronous gastric cancer.

Shibukawa N, Ouchi S, Wakamatsu S, Wakahara Y, Kaneko A.

World J Gastrointest Oncol. 2017 Aug 15;9(8):327-332. doi: 10.4251/wjgo.v9.i8.327.

4.

Helicobacter pylori sabA gene is associated with iron deficiency anemia in childhood and adolescence.

Kato S, Osaki T, Kamiya S, Zhang XS, Blaser MJ.

PLoS One. 2017 Aug 30;12(8):e0184046. doi: 10.1371/journal.pone.0184046. eCollection 2017.

5.

Advanced non-cardia gastric cancer and Helicobacter pylori infection in Vietnam.

Binh TT, Tuan VP, Dung HDQ, Tung PH, Tri TD, Thuan NPM, Khien VV, Hoan PQ, Suzuki R, Uchida T, Trang TTH, Yamaoka Y.

Gut Pathog. 2017 Aug 17;9:46. doi: 10.1186/s13099-017-0195-8. eCollection 2017.

6.

The Exceptional Oncogenicity of HTLV-1.

Tagaya Y, Gallo RC.

Front Microbiol. 2017 Aug 2;8:1425. doi: 10.3389/fmicb.2017.01425. eCollection 2017. Review.

7.

In vitro Cytotoxic Activities of the Oral Platinum(IV) Prodrug Oxoplatin and HSP90 Inhibitor Ganetespib against a Panel of Gastric Cancer Cell Lines.

Klameth L, Rath B, Hamilton G.

J Cancer. 2017 Jul 1;8(10):1733-1743. doi: 10.7150/jca.17816. eCollection 2017.

8.

Second-line therapy for Helicobacter pylori eradication causing antibiotic-associated hemorrhagic colitis.

Tanaka K, Fujiya M, Sakatani A, Fujibayashi S, Nomura Y, Ueno N, Kashima S, Goto T, Sasajima J, Moriichi K, Okumura T.

Ann Clin Microbiol Antimicrob. 2017 Aug 14;16(1):54. doi: 10.1186/s12941-017-0230-0.

9.

High miss rate for gastric superficial cancers at endoscopy: what is necessary for gastric cancer screening and surveillance using endoscopy?

Sekiguchi M, Oda I.

Endosc Int Open. 2017 Aug;5(8):E727-E728. doi: 10.1055/s-0043-112245. Epub 2017 Aug 7. No abstract available.

10.

Gastric superficial neoplasia: high miss rate but slow progression.

Shimodate Y, Mizuno M, Doi A, Nishimura N, Mouri H, Matsueda K, Yamamoto H.

Endosc Int Open. 2017 Aug;5(8):E722-E726. doi: 10.1055/s-0043-110076. Epub 2017 Aug 7.

11.

Prevention of Gastric Cancer: Eradication of Helicobacter Pylori and Beyond.

Tsukamoto T, Nakagawa M, Kiriyama Y, Toyoda T, Cao X.

Int J Mol Sci. 2017 Aug 3;18(8). pii: E1699. doi: 10.3390/ijms18081699. Review.

12.

Helicobacter pylori vacA genotype is a predominant determinant of immune response to Helicobacter pylori CagA.

Link A, Langner C, Schirrmeister W, Habendorf W, Weigt J, Venerito M, Tammer I, Schlüter D, Schlaermann P, Meyer TF, Wex T, Malfertheiner P.

World J Gastroenterol. 2017 Jul 14;23(26):4712-4723. doi: 10.3748/wjg.v23.i26.4712.

13.
14.

The serum pepsinogen levels for risk assessment of gastric neoplasms: New proposal from a case-control study in Korea.

Cho JH, Jeon SR, Kim HG, Jin SY, Park S.

Medicine (Baltimore). 2017 Jul;96(29):e7603. doi: 10.1097/MD.0000000000007603.

15.

Risk factors for metachronous gastric carcinoma development after endoscopic resection of gastric dysplasia: Retrospective, single-center study.

Moon HS, Yun GY, Kim JS, Eun HS, Kang SH, Sung JK, Jeong HY, Song KS.

World J Gastroenterol. 2017 Jun 28;23(24):4407-4415. doi: 10.3748/wjg.v23.i24.4407.

16.

The prevalence of gastric heterotopia of the proximal esophagus is underestimated, but preneoplasia is rare - correlation with Barrett's esophagus.

Peitz U, Vieth M, Evert M, Arand J, Roessner A, Malfertheiner P.

BMC Gastroenterol. 2017 Jul 12;17(1):87. doi: 10.1186/s12876-017-0644-3.

17.

Association between Gastric Cancer Risk and Serum Helicobacter pylori Antibody Titers.

Shuto M, Fujioka T, Matsunari O, Okamoto K, Mizukami K, Okimoto T, Kodama M, Takigami S, Seguchi C, Nonaka Y, Sato R, Yamaoka Y, Murakami K.

Gastroenterol Res Pract. 2017;2017:1286198. doi: 10.1155/2017/1286198. Epub 2017 Jun 11.

18.

Analyzing the role of CagV, a VirB8 homolog of the type IV secretion system of Helicobacter pylori.

Kumar N, Shariq M, Kumar A, Kumari R, Subbarao N, Tyagi RK, Mukhopadhyay G.

FEBS Open Bio. 2017 May 24;7(7):915-933. doi: 10.1002/2211-5463.12225. eCollection 2017 Jul.

19.

A systematic review and meta-analysis of the role of Helicobacter pylori eradication in preventing gastric cancer.

Rokkas T, Rokka A, Portincasa P.

Ann Gastroenterol. 2017;30(4):414-423. doi: 10.20524/aog.2017.0144. Epub 2017 Apr 7.

20.

Validation of a Novel Immunoline Assay for Patient Stratification according to Virulence of the Infecting Helicobacter pylori Strain and Eradication Status.

Formichella L, Romberg L, Meyer H, Bolz C, Vieth M, Geppert M, Göttner G, Nölting C, Schepp W, Schneider A, Ulm K, Wolf P, Holster IL, Kuipers EJ, Birkner B, Soutschek E, Gerhard M.

J Immunol Res. 2017;2017:8394593. doi: 10.1155/2017/8394593. Epub 2017 May 30.

Supplemental Content

Support Center